Clinical / Pharmaceutical

Octreotide

Sandostatin · octreotide acetate · SMS 201-995

Somatostatin analog, FDA-approved 1988 (Sandostatin) for acromegaly and neuroendocrine tumors. Branded short-acting product is already a solution (50/100/500 mcg/mL ampuls). This leaf covers mcg reconstitution for compounded or lyophilized acetate vials. Sandostatin LAR is a depot - do not use this calculator for LAR kits.

Quick answer

What it is: Somatostatin analog, FDA-approved 1988 (Sandostatin) for acromegaly and neuroendocrine tumors.

Typical research dose: 50-200 mcg SC 2–3×/day (labeled acromegaly/NET starting range; titrate)

Reconstitution calculator ↓

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: High·1 peer-reviewed citation

Typical research dose

50-200 mcg SC 2–3×/day (labeled acromegaly/NET starting range; titrate)

Frequency

2–3× daily (short-acting SC); LAR is clinic-only

Half-life

~1.7–1.9 hours SC

Common vials

1 mg / 2 mg / 5 mg

CAS

83150-76-9

Molecular weight

~1019 Da (free peptide)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Metabolic / weight3/10
Labeled for acromegaly and NETs, which can change weight. Not a fat-loss peptide.

Compound card

Class: Somatostatin analog (Sandostatin; not LAR depot math)
Formula: Octreotide acetate (cyclic octapeptide)
Status: FDA-approved

Dose it

2 mg + 2 mL BAC water → 1 mg/mL · 50 mcg ≈ 5 units (U-100)

Open in calculator

How it works

Octreotide is a somatostatin analog (sst2/sst5). Sandostatin short-acting injection is already a solution (50/100/500 mcg/mL ampuls; multi-dose 200 and 1,000 mcg/mL). Plasma t½ ~1.7–1.9 hours; action can last up to ~12 hours.

This calculator is for lyophilized/compounded acetate vials in mg. Do not run LAR depot kits through it - LAR is a different reconstitution (milky suspension, gluteal, clinic).

Source: FDA Sandostatin label (DailyMed octreotide acetate)

Ampuls vs powder vs LAR

If you have a Sandostatin ampul, concentration is already on the label - skip powder math. If you have LAR, stop and use the LAR kit instructions. Powder math here is for compounded/lyophilized acetate.

Research Use Cases

✓Acromegaly / NETs: High

Dosing

Phase	Dose	Frequency	Notes
Labeled short-acting (acromegaly/NET starting)	50–200 mcg	2–3× daily SC	Titrate per PI. This is not a research peptide protocol.

Administration

Route / form

Deep SC or IV (labeled). Short-acting is not LAR.

Timing

Follow the PI.

Empty stomach?

No - Food timing is not critical.

Timeline

Hours

GH/symptom control window up to ~12 h depending on tumor type (label).

Who it is for

Acromegaly / NETs

High

FDA-approved since 1988. This site does syringe math, not oncology.

Reconstitution

Vial	Water	Concentration	Example dose
2 mg lyophilized	2 mL BAC	1 mg/mL	Compounded lyophilized cakes only. Branded ampuls skip recon. LAR kits are forbidden math here.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Prescription. Gallbladder disease, glucose dysregulation (hypo- and hyperglycemia), bradycardia, steatorrhea. Drug interactions (e.g. cyclosporine, insulin). LAR is a different product.

Regulatory & Legal Status

FDA Status (US)

Approved

FDA-approved 1988 as Sandostatin® (acromegaly, NETs). LAR depot is a separate clinic product

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Prescription Drug

US Compounding: Available via licensed pharmacy Rx

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

This site will not treat acromegaly or carcinoid from an octreotide page.
Gallbladder and glucose effects are on the label.

Verdict

Octreotide is Sandostatin. Short-acting SC is already a solution in branded ampuls. LAR is a clinic depot. Do not use this calculator for LAR. Not a DIY acromegaly drug.

Interactions & Contraindications

Prescription. Gallbladder disease, glucose dysregulation (hypo- and hyperglycemia), bradycardia, steatorrhea. Drug interactions (e.g. cyclosporine, insulin). LAR is a different product.

Frequently Asked Questions

My vial is 500 mcg/mL already.▼

Then concentration is 500 mcg/mL. On U-100, 1 unit = 5 mcg. A 100 mcg dose is 20 units. Ignore the powder fields.

Is this tesamorelin’s opposite?▼

Roughly: octreotide suppresses GH; tesamorelin stimulates it. Different indications. Do not stack them as a DIY endocrine experiment.

References

Novartis / FDA DailyMed “Sandostatin (octreotide acetate) injection label.” US PI (current).

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library